105 citations
,
September 1995 in “Journal of The American Academy of Dermatology” This review discusses the use of recombinant cytokines as therapeutic agents in clinical settings and describes the range of cutaneous complications associated with their use, including both minor and severe skin reactions.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.
53 citations
,
May 2001 in “The American journal of the medical sciences” This article reviews common skin eruptions in chemotherapy patients and discusses how recognizing these patterns can help avoid unnecessary changes to cancer treatment; it reports no new clinical results.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.
18 citations
,
January 1999 in “CNS Drugs” This review discusses challenges in managing cutaneous drug reactions to anticonvulsants and reports no new clinical findings; the authors emphasize the complexity of discontinuing or rechallenging suspected agents.